Given the increasing evidence that brain circuits regulate energy homeostasis and body weight, the widespread use of GLP-1-based therapies for obesity and type 2 diabetes treatment [2] and the variable response of patients to these therapies [22], further studying of GLP-1R levels variations in key cell subpopulations of the human hypothalamus is of clinical interest. The gene discussed is GLP1R; the disease is obesity disorder.